MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

uniQure NV

Cerrado

10.6 7.07

Resumen

Variación precio

24h

Actual

Mínimo

9.68

Máximo

10.78

Métricas clave

By Trading Economics

Ingresos

-29M

-73M

Ventas

2.9M

5.2M

BPA

-1.442

Margen de beneficio

-1,403.199

Empleados

209

EBITDA

-28M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+266.2% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

84M

674M

Apertura anterior

3.53

Cierre anterior

10.6

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

uniQure NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 dic 2024, 15:18 UTC

Principales Movimientos del Mercado

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Comparación entre iguales

Cambio de precio

uniQure NV Esperado

Precio Objetivo

By TipRanks

266.2% repunte

Estimación a 12 meses

Media 36.29 USD  266.2%

Máximo 70 USD

Mínimo 18 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para uniQure NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.38 / 14.95Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.